A recent genomic analysis of pretreatment samples as well samples obtained at that time of progression in R/R CLL patients treated with Pirtobrutinib, identified on-target BTK mutations and also downstream PLCγ2 mutations, that allowed escape from the BTK inhibition [77]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.